All
Breaking Down The Results of The ALPHA/ALPHA2 Study in Large B-Cell Lymphoma
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Camizestrant Combo Improves Progression Time in HR+/HER2– Breast Cancer
Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in HR+/HER2– advanced breast cancer.
Cema-Cel Has Durable Responses in in Relapsed/Refractory Large B-Cell Lymphoma
Treatment with the CAR T-cell therapy cema-cel demonstrated durable responses in patients with relapsed/refractory large B-cell lymphoma.
Chemoradiation Benefits for Cervical Cancer May Decline After Age 80
Chemoradiation improves survival in cervical cancer patients, but benefits may decline after age 80, according to a study using SEER data.
A Second Chance I Never Knew I Had After Lymphoma
A year ago, I was told my lymphoma had worsened, but a miraculous turn of events spared me from aggressive chemotherapy, making me grateful for each day of life.
An Expert Highlights His Key Takeaways From The 2025 ASCO GU Symposium
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Pregnancy After Glioma Diagnosis Associated With Worse Progression Time
For female patients with glioma, pregnancy after receiving a diagnosis of glioma is associated with worse progression-free survival times.
There is a Growing Need For Genetic Testing and Precision Medicine in GU Cancers
Dr. Chandler Park helps patients with genitourinary cancers, including both prostate and bladder, understand the importance of genetic testing.
Fractionated Reirradiation is Safe and Feasible in High-Grade Glioma
Fractionated reirradiation is safe and feasible, suggesting higher reirradiation dose may be feasible in patients with recurrent high-grade glioma.
ctDNA Alone ‘Not Sufficient’ When Monitoring Patients With Colorectal Cancer
The addition of ctDNA testing to radiographic surveillance resulted in curative surgical intervention for 1.6% of patients with colorectal cancer.
My Cousin and I Journey Through Breast, Lung, Pancreatic and Prostate Cancer
After realizing that a stronger support system would have helped me emotionally and spiritually in my cancer journey, I committed myself to being there for my cousin.
Datroway May Be Effective in Non-Small Cell Lung Cancer Subtypes
Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic alterations, including EGFR and ALK subgroups.
Moving Beyond Chemotherapy: How Biomarker Testing is Changing Cancer Care
Metronomic Capecitabine and an AI Improve Survival in HR+/HER2– Metastatic Breast Cancer
Metronomic capecitabine plus an aromatase inhibitor improved survival outcomes in hormone receptor-positive, HER2-negative metastatic breast cancer.
Off-The-Shelf CAR T Therapy Elicits Responses in Large B-Cell Lymphoma
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
A Study Investigates If CAR T Therapy Directly Causes Secondary Malignancies
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
The Bittersweet Blessings of Being a Young Adult Cancer Survivor
Being a young adult cancer survivor is bittersweet, bringing both unique struggles and unexpected blessings that shape my life, career and perspective.
Minimal Residual Disease Testing’s Variability Across Cancer Types
Dr. Christopher R. Flowers explains that MRD testing varies by cancer type, with results impacting recurrence risk and monitoring based on disease characteristics.
What Patients With Breast Cancer Need to Know About Itovebi and Blood Sugar
An expert explained a potential side effect associated with treatment consisting of Itovebi for breast cancer.
Delving Into Clinical Research For Patients With Breast Cancer
Dr. Yuan Yuan breaks down studies for patients with breast cancer, such as the phase 3 CompassHER2 RD Trial.
Clinical Trials to Watch in Triple-Negative Breast Cancer
An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.
Meet Bladder Cancer Warrior Mike and His Wife and Care Partner, Heidi
FDA Accepts sBLA For Opdivo Plus Yervoy For Some Patients with mCRC
The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult and pediatric patients with colorectal cancer.
FDA Accepts NDA For Dordaviprone in H3 K27M-Mutant Diffuse Glioma
A New Drug Application has been accepted seeking accelerated approval for dordaviprone for patients with recurrent H3 K27M-mutant diffuse glioma, with a target action date of Aug. 18.
FDA Accepts Priority Review for Pre- and Postsurgical Keytruda in HNSCC
The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally advanced head and neck cancer.
Treating Lymphedema with a Simple Trinket
Buying a pretty bracelet was healing because it let me look at my lymphedema in a new light.
Understanding Biliary Tract Cancer and The Current Standard of Care
An expert explains what biliary tract cancers are and the current landscape of treatment as well as future advancements.
Some KRAS Mutations Associated With Worse Outcomes in Pancreatic Cancer
In patients with pancreatic ductal adenocarcinoma, KRAS G12D and G12V mutations hare associated with worse patient outcomes, researchers have found.
Neoadjuvant Opdivo Combo Elicits Statistically Significant OS Findings in Resectable NSCLC
Neoadjuvant Opdivo with platinum-doublet chemo had a statistically significant and clinically meaningful improvement versus chemo alone in resectable NSCLC.
What Patients With Cancer Should Know About DPD Deficiency Prior to Chemo
Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it.
